Britain’s AstraZeneca has launched phase three trials of an antibody combination drug, called AZD7442, that it hopes could be used to protect those at risk of contracting the coronavirus disease for up to 12 months.
from Hindustan Times - india https://ift.tt/3nLKRBU
No comments:
Post a Comment